Sydney-based radiopharmaceutical company AdvanCell has appointed Andrew Kay as director and chair-elect of its board.
According to a company announcement, Kay brings several years of leadership experience in the biotech and pharmaceutical sectors, having played key roles in the development and commercialization of several innovative therapies. As CEO of Algeta ASA, he oversaw the development and global launch of Xofigo, the first alpha-emitting radiopharmaceutical approved for treating bone metastases in patients with castration-resistant prostate cancer.
His career also includes senior positions at major pharmaceutical companies including Novartis, Zeneca, Eli Lilly and Sandoz.
“I am honored to be joining AdvanCell at such an exciting and pivotal stage, with the unveiling of the company’s first and very promising Phase 1 trial results with ADVC001 in prostate cancer at ESMO, and the establishment of manufacturing capabilities in the U.S. to support global late-stage development. My time with Algeta gave me important insights into the therapeutic benefits of alpha-emitting therapies for cancer, including those linked to precision targeting molecules, which I believe will transform the oncology treatment landscape,” Kay said in a statement.
AdvanCell is focused on developing next-generation cancer therapies using targeted alpha-emitting radionuclides, a field gaining attention for its potential to precisely destroy cancer cells while minimizing harm to healthy tissue.
